Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death and is
currently the main event leading to death in patients with cirrhosis. Evolving information …

Hepatocellular carcinoma (HCC) is a major health problem. Most patients with HCC
experience a recurrence after resection/ablation or are diagnosed at advanced stages …

The knowledge and understanding of all aspects of liver cancer [this including
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA)] have …

Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Multiple
treatment options are available for HCC including curative resection, liver transplantation …

Background & Aims There are no clinical data/markers to predict improved survival in
patients with hepatocellular carcinoma treated with sorafenib. Majority of sorafenib adverse …

Recent advancements have improved the management of patients with liver cancer. Results
of studies have informed how to stage and decide the optimal treatment option for each …

Background: Gallbladder cancers and cholangiocarcinomas make up a heterogenous group
of tumours with a poor prognosis in advanced stages. On the basis of evidence of …

Hepatocellular carcinoma (HCC) is one of the most frequent tumors worldwide. The majority
of HCC cases occur in patients with chronic liver disease. Despite regular surveillance to …

Liver cancer was traditionally treated by surgery or interventional ablative treatments, or, if
these options were not feasible, by best supportive care. Since 2008, systemic therapy with …

Background & Aims IGF-IR is implicated in hepatic carcinogenesis. This and preliminary
evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I …